Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.24

-3.7%

12:01 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Liebman who wrote (466)	12/22/1999 9:11:00 AM
From: Biomaven	Read Replies (2) of 52153

Larry, Left at the altar feels particularly bad when there's a great big orgy going on across the street involving the genomics/mAb companies. BTRN is up substantially off its highs, so not really left at the altar. Still lots of leverage if things work out, though. VRTX fits your description better - however value plays just aren't where the action is right now, and it's hard to know when the market will change its mind. Certainly excellent science (look at their unbelievable success in getting candidate drugs to the clinic), but I suspect it's not going to move much until some of their candidates advance further. NPSP is a good place to look - beaten down by the merger and BVF selling. BPUR is an interesting but volatile play that should do well next year. IGEN is also interesting, but will be driven short-term by the Roche dispute. This is one that could easily attract substantial attention down the road. Altogether bargains are much thinner on the ground than a year ago. We've had a fantastic 6 week run here, and it appears to be not over yet. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next